Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Adult
Benzoates
/ therapeutic use
Humans
Hydrazines
/ therapeutic use
Purpura, Thrombocytopenic, Idiopathic
/ chemically induced
Pyrazoles
Receptors, Fc
/ therapeutic use
Receptors, Thrombopoietin
/ agonists
Recombinant Fusion Proteins
/ therapeutic use
Thiazoles
Thiophenes
Thrombocytopenia
/ drug therapy
Thrombopoietin
avatrombopag
eltrombopag
immune thrombocytopenia
romiplostim
thrombopoietin receptor agonist
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
15
01
2022
received:
01
11
2021
accepted:
26
01
2022
pubmed:
19
2
2022
medline:
29
4
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another. Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral TPO-RA. We performed a retrospective observational study of adults with ITP who switched from eltrombopag or romiplostim to avatrombopag at four US tertiary ITP referral centres. Forty-four patients were included, with a mean ITP duration of 8.3 years and a median (range) of four prior ITP treatments. On avatrombopag, 41/44 patients (93%) achieved a platelet response (≥50 × 10
Identifiants
pubmed: 35179784
doi: 10.1111/bjh.18081
pmc: PMC9306832
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
Receptors, Fc
0
Receptors, Thrombopoietin
0
Recombinant Fusion Proteins
0
Thiazoles
0
Thiophenes
0
avatrombopag
3H8GSZ4SQL
Thrombopoietin
9014-42-0
romiplostim
GN5XU2DXKV
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-366Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Haematologica. 2016 Dec;101(12):1443-1445
pubmed: 27903709
Blood Adv. 2019 Dec 10;3(23):3829-3866
pubmed: 31794604
Am J Hematol. 2018 Jan;93(1):58-64
pubmed: 28983953
Haematologica. 2013 Jun;98(6):881-7
pubmed: 23445876
Blood. 2009 Mar 12;113(11):2386-93
pubmed: 19005182
Br J Haematol. 2018 Nov;183(3):479-490
pubmed: 30191972
Br J Haematol. 2022 May;197(3):359-366
pubmed: 35179784
N Engl J Med. 2007 Nov 29;357(22):2237-47
pubmed: 18046028
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
Br J Haematol. 2018 Oct;183(2):168
pubmed: 29978577
Int J Hematol. 2013 Jul;98(1):10-23
pubmed: 23821332
Haematologica. 2016 Dec;101(12):1479-1488
pubmed: 27515246
Ther Adv Hematol. 2019 May 09;10:2040620719837906
pubmed: 31156798
Expert Opin Pharmacother. 2021 Feb;22(3):273-280
pubmed: 33095074
J Blood Med. 2019 Sep 05;10:313-321
pubmed: 31565009
Am J Hematol. 2010 Mar;85(3):174-80
pubmed: 20131303
Semin Thromb Hemost. 2020 Apr;46(3):275-288
pubmed: 31830764
Haematologica. 2019 Jun;104(6):1112-1123
pubmed: 31073079
Lancet. 2008 Feb 2;371(9610):395-403
pubmed: 18242413